NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Contents
- AUTHORS, CONTRIBUTORS, AND REVIEWERS
- PREFACE
- COMMONLY USED ABBREVIATIONS AND ACRONYMS
- EXECUTIVE SUMMARY
- 1.0. BACKGROUND
- 2.0. PROBLEM FORMULATION
- 3.0. OVERVIEW OF EVIDENCE IDENTIFICATION FOR SYNTHESIS AND DOSE-RESPONSE ANALYSIS
- 4.0. EVIDENCE SYNTHESIS: OVERVIEW OF INCLUDED STUDIES
- 5.0. EVIDENCE INTEGRATION AND HAZARD CHARACTERIZATION
- 6.0. DERIVATION OF VALUES
- APPENDIX A. LITERATURE SEARCH STRATEGY
- APPENDIX B. DETAILED PECO CRITERIA
- APPENDIX C. STUDY EVALUATION METHODS
- APPENDIX D. HAWC USER GUIDE AND FREQUENTLY ASKED QUESTIONS
- APPENDIX E. ADDITIONAL DATA FIGURES
- APPENDIX F. BENCHMARK DOSE MODELING RESULTS
- APPENDIX G. QUALITY ASSURANCE
- APPENDIX H. REFERENCES
DISCLAIMER: This document has been reviewed in accordance with U.S. Environmental Protection Agency policy and approved for publication. Mention of trade names or commercial products does not constitute endorsement or recommendation for use.
- NLM CatalogRelated NLM Catalog Entries
- Provisional Peer-Reviewed Toxicity Values for Perfluorobutane Sulfonic Acid (CAS...Provisional Peer-Reviewed Toxicity Values for Perfluorobutane Sulfonic Acid (CASRN 375-73-5) and Related Compound Potassium Perfluorobutane Sulfonate (CASRN 29420-49-3)
- zinc finger protein GLI1 isoform 1 [Homo sapiens]zinc finger protein GLI1 isoform 1 [Homo sapiens]gi|4885279|ref|NP_005260.1|Protein
Your browsing activity is empty.
Activity recording is turned off.
See more...